Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. www.mayoclinic.org › drugs-supplements › doxepin-oral-routeDoxepin (oral route) - Mayo Clinic

    1 Φεβ 2024 · Description. Doxepin is used to treat anxiety or depression. It is also used to treat insomnia (trouble with sleeping). Doxepin is a tricyclic antidepressant (TCA). It works on the central nervous system (CNS) to increase levels of certain chemicals in the brain. This medicine is available only with your doctor's prescription.

  2. 6 Απρ 2023 · Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition. Lifestyle and home remedies In some cases, self-care might be a way for you to deal with obstructive sleep apnea and possibly central sleep apnea.

  3. 11 Ιουλ 2023 · Various devices are available to deliver oxygen to your lungs. Medicines. Medicines such as acetazolamide have been used to stimulate breathing in people with central sleep apnea. These medicines might be prescribed to help your breathing as you sleep if you can't tolerate positive airway pressure.

  4. Obstructive sleep apnea (OSA) is a disorder in which a person frequently stops breathing during his or her sleep. It results from an obstruction of the upper airway during sleep that occurs because of inadequate motor tone of the tongue and/or airway dilator muscles.

  5. 11 Ιαν 2024 · Initial dose: 75 mg orally once a day. Maintenance dose: 75 to 150 mg orally once a day or in divided doses; patients with very mild disease may be adequately controlled with 25 to 50 mg per day. Maximum dose: 150 mg/day.

  6. One of the first major reports describing the possible adverse consequences of sleep apnea came from the Henry Ford Hospital in 1988. 1 A significant increase in mortality was reported during an 8-year period in patients with severe OSAS compared with those with less severe OSAS.

  7. Abstract. Doxepin, a sedating tricyclic drug, at 3 mg and 6 mg doses was recently approved by the U.S. food and drug administration (FDA) for the treatment of insomnia. The objective of this systematic review was to obtain a precise summary of the efficacy and safety of doxepin as a hypnotic.